Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
      • Real World Data
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Sutro Biopharma

Evaluate

Thumbnail
May 03, 2023

Mirasol knockout puts the pressure on Sutro

Apparently knockout ovarian cancer data put Immunogen’s Elahere on track for full approval, a risk Sutro investors have decided to ignore.

March 30, 2023

Major readouts on the horizon for small developers

Important ovarian cancer data are ahead for Immunogen and Mersana, while Disc Medicine eyes a rare metabolic disorder.

Article image
Vantage logo
March 16, 2023

World ADC 2023 – targeting the folate receptor rises from the ashes

Zymeworks, Profoundbio, Elucida and Immunogen itself piggyback on Elahere’s success to develop a better antibody-drug conjugate.

Article image
Vantage logo
January 10, 2023

JP Morgan 2023 – Sutro makes its pitch to beat Immunogen

The group reckons it can target twice as many ovarian cancer patients, but an important disclosure shows that its case it not clear-cut.

Article image
Vantage logo
December 09, 2022

Not so fast for some accelerated approvals

The US conditional approval pathway has enjoyed years of expansion, but now the FDA is trying to put the toothpaste back into the tube.

Article image
Vantage logo
November 15, 2022

Immunogen puts Sutro on alert

Article image
Vantage logo
June 28, 2022

Sutro’s next-generation tech gets a thumbs up from Astellas

Article image
Vantage logo
March 21, 2022

Immunogen’s Mirasol trial goes down to the wire

Full data from mirvetuximab’s Soraya study make investors nervous as readout of the Mirasol confirmatory trial looms.

Article image
Vantage logo
January 06, 2022

Sutro’s folate challenge to Immunogen hits a problem

In a battle of anti-folate receptor α projects STRO-002 outperforms mirvetuximab, but Sutro investors are not celebrating.

Article image
Vantage logo
December 31, 2021

Biopharma developments over the Christmas period

Investors nursing a fall in biotech indices now have to digest the failure of Bridgebio's acoramidis in 2021’s last important catalyst.

Article image
Vantage logo
November 30, 2021

Immunogen’s perseverance pays off

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up